Regencell Bioscience Holdings Limited (RGC)

NASDAQ: RGC · IEX Real-Time Price · USD
31.55
-0.28 (-0.88%)
Aug 12, 2022 12:32 PM EDT - Market closed
-0.88%
Market Cap 410.56M
Revenue (ttm) n/a
Net Income (ttm) -1.35M
Shares Out 13.01M
EPS (ttm) -0.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 695
Open 31.55
Previous Close 31.83
Day's Range 31.55 - 31.55
52-Week Range 6.00 - 59.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About RGC

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. [Read more...]

Industry Drug Manufacturers-Specialty & Generic
IPO Date Jul 16, 2021
Employees 13
Stock Exchange NASDAQ
Ticker Symbol RGC
Full Company Profile

Financial Performance

Financial Statements

News

Sector Rotation And 9 Stocks To Watch During A Recession

Is the United States heading toward a recession? This has been the looming question on the minds of Americans since inflation topped at 8.5% in March, matched with other indicators such as rising intere...

Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigati...

HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (NASDAQ: RGC): Results of EARTH efficacy trial   EARTH Efficacy Trials Period of trial 30 January 2022 – 31 March 2022 (E...

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focusing on the research, development and...

Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Vi...

LOS ANGELES, CA / ACCESSWIRE / March 1, 2022 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with the team from Regencell Bioscience Holdings ...

Regencell Bioscience's COVID-19 Candidate Shows Encouraging Action On Mild To Moderate Symptoms

Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the results from the EARTH efficacy trial of its COVID-19 candidate. RGC-COV19 (Regencell Bioscience (RGCA-CV01) liquid formulation) is an o...

Regencell Bioscience's Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients i...

HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”) today announced the results from an analysis of a total of 37 individuals en...

Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercializati...

Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEO

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercializati...

Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercializati...

Regencell Bioscience Stock Jumps On Formation Of COVID-19 Treatment Focused Joint Venture

Regencell Bioscience Holdings Ltd's (NASDAQ: RGC) subsidiary in Hong Kong has entered into a joint venture agreement with Honor Epic Enterprises Limited to offer COVID-19 related treatments. The joint v...

Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), today announced that Regencell Bioscience Limited (“Regencell HK”), the Company's wholly-o...

Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter's Over-Allotment Option

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company that focuses on research, development and commercializati...

Regencell Bioscience Holdings Limited Releases CEO Letter to Shareholders

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company today released a letter from Yat-Gai Au, Founder and Chi...

Regencell Bioscience Holdings Limited Announces Closing of Initial Public Offering

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development and commercializati...

7 Companies Begin Trading. Here's How They're Doing.

The group is diverse—a fintech, three biotechs, a real-estate investment manager, a bioscience company, and a pharmaceutical glassmaker.

Other symbols: BLNDBRDGERASIMGOSTVN

Regencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development and commercializati...